OIS@AAO
TearScience Inc. CEO and Co-Founder Tim Willis emphasized that his company was founded for a single reason: to be the evaporative dry eye expert, and…
Read MoreWaveTec Vision Systems ORA system is the first intra-operative diagnostic tool on the market to enhance visual outcomes in cataract surgery. It allows surgeons, in…
Read MoreAlimera Sciences Inc. is ready to launch in the US its recently approved intravitreal implant, Iluvien, for treating diabetic macular edema. President and CEO Dan…
Read MoreMC2 Biotek Group’s Co-Founder and President Jesper J. Lange updated attendees on the company’s PAD technology, which may make existing drugs easier to use. The…
Read MoreThomas W. Chalberg, PhD presented an update on Avalanche Biotechnologies Inc.’s pipeline of products emerging from its integrated gene therapy discovery, development, and manufacturing platform,…
Read More[creativ_media type=”vimeo” url=”https://vimeo.com/110730931″] Vicken Karageozian, MD, Co-Founder and CTO of Allegro Opthalmics LLC, updated the OIS audience on the clinical trial progress of Luminate, a…
Read MoreCEO David R. Guyer, MD reports that Phase III clinical trials of Ophthotech Corp.’s Fovista, a first-in-class anti-PDGF agent for wet AMD combination therapy, are…
Read MoreMonoclonal antibody company Xoma Corp. shared its new strategy of developing an internal pipeline of potential therapeutics. The company’s lead molecule is gevokizumab, a monoclonal…
Read MoreNovaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther.…
Read MoreEd Timm, President and CEO of Mobius Therapeutics LLC, provided an update on the investigations into extending the company’s Mitosol platform, presently used to administer…
Read MoreGrayBug LLC is conducting preclinical work on its microparticle anti-VEGF compound GB-102, an extended-release injectable for wet AMD. The platform encapsulates the active drug ingredient…
Read MoreAmarpreet Sawhney, PhD, President and CEO of Ocular Therapeutix shared his company’s vision: to transform the treatment of eye diseases with sustained release therapeutics. Ocular’s…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")